Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer’s disease
暂无分享,去创建一个
F. Cheng | Yadi Zhou | Lang Li | Yuan Hou | Jiansong Fang | S. Stauffer | J. Cummings | A. Pieper | Pengyue Zhang | Juan Tan | Chienwei Chiang | Y. Hou
[1] John F. Ouyang,et al. Transcriptional signature in microglia associated with Aβ plaque phagocytosis , 2021, Nature Communications.
[2] William T. Ralvenius,et al. APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia , 2021, Science Translational Medicine.
[3] J. Cummings,et al. AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery , 2021, Alzheimer's Research & Therapy.
[4] J. Trojanowski,et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative , 2020, Molecular Psychiatry.
[5] R. Nussinov,et al. Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing , 2020, Medicinal research reviews.
[6] T. Strovas,et al. Synergistic toxicity between tau and amyloid drives neuronal dysfunction and neurodegeneration in transgenic C. elegans. , 2020, Human molecular genetics.
[7] Rosemary J. Jackson,et al. Amyloid Beta and Tau Cooperate to Cause Reversible Behavioral and Transcriptional Deficits in a Model of Alzheimer’s Disease , 2019, Cell reports.
[8] A. Hingorani,et al. Lipid lowering and Alzheimer disease risk: A mendelian randomization study , 2019, Annals of neurology.
[9] L. Tan,et al. Diabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 144 prospective studies , 2019, Ageing Research Reviews.
[10] D. Holtzman,et al. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies , 2019, Cell.
[11] Mendelian randomization indicates that TNF is not causally associated with Alzheimer's disease , 2019, Neurobiology of Aging.
[12] R. Nussinov,et al. A Systems Pharmacology Approach Uncovers Wogonoside as an Angiogenesis Inhibitor of Triple-Negative Breast Cancer by Targeting Hedgehog Signaling. , 2019, Cell chemical biology.
[13] Hinrich W. H. Göhlmann,et al. A genetics-led approach defines the drug target landscape of 30 immune-related traits , 2019, Nature Genetics.
[14] J. Sutcliffe,et al. A Bayesian framework that integrates multi-omics data and gene networks predicts risk genes from schizophrenia GWAS data , 2019, Nature Neuroscience.
[15] S. Davis,et al. Mechanisms Associated with Type 2 Diabetes as a Risk Factor for Alzheimer-Related Pathology , 2019, Molecular Neurobiology.
[16] Nick C. Fox,et al. Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. , 2018, Nature Medicine.
[17] Benjamin A. Logsdon,et al. Genome-wide RNAseq study of the molecular mechanisms underlying microglia activation in response to pathological tau perturbation in the rTg4510 tau transgenic animal model , 2018, Molecular Neurodegeneration.
[18] F. Tanaka,et al. Microglia in Alzheimer's Disease: Risk Factors and Inflammation , 2018, Front. Neurol..
[19] C. Gaiteri,et al. The Molecular and Neuropathological Consequences of Genetic Risk for Alzheimer's Dementia , 2018, Front. Neurosci..
[20] J. Klappenbach,et al. Human Alzheimer’s disease gene expression signatures and immune profile in APP mouse models: a discrete transcriptomic view of Aβ plaque pathology , 2018, Journal of Neuroinflammation.
[21] S. Makin,et al. The amyloid hypothesis on trial , 2018, Nature.
[22] E. Guney,et al. Proximal Pathway Enrichment Analysis for Targeting Comorbid Diseases via Network Endopharmacology , 2018, Pharmaceuticals.
[23] Y. Son,et al. Sildenafil protects neuronal cells from mitochondrial toxicity induced by β-amyloid peptide via ATP-sensitive K+ channels. , 2018, Biochemical and biophysical research communications.
[24] D. Llewellyn,et al. Individual and Area-Based Socioeconomic Factors Associated With Dementia Incidence in England , 2018, JAMA psychiatry.
[25] Lindsay A. Farrer,et al. Genome-wide association study of Alzheimer's disease endophenotypes at prediagnosis stages , 2018, Alzheimer's & Dementia.
[26] Julia M. Barbarino,et al. PharmGKB: A worldwide resource for pharmacogenomic information , 2018, Wiley interdisciplinary reviews. Systems biology and medicine.
[27] Alasdair J. G. Gray,et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY , 2017, Nucleic Acids Res..
[28] David S. Wishart,et al. DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..
[29] D. Brat,et al. (−)-P7C3-S243 Protects a Rat Model of Alzheimer’s Disease From Neuropsychiatric Deficits and Neurodegeneration Without Altering Amyloid Deposition or Reactive Glia , 2017, Biological Psychiatry.
[30] Aidan Budd,et al. SignaLink: Multilayered Regulatory Networks. , 2018, Methods in molecular biology.
[31] Dohyun Han,et al. Molecular and functional signatures in a novel Alzheimer’s disease mouse model assessed by quantitative proteomics , 2018, Molecular Neurodegeneration.
[32] J. Götz,et al. Tau-based therapies in neurodegeneration: opportunities and challenges , 2017, Nature Reviews Drug Discovery.
[33] David S. Park,et al. β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease , 2017, Science.
[34] Daniel B. McClatchy,et al. Amyloid accumulation drives proteome-wide alterations in mouse models of Alzheimer’s disease like pathology , 2017, bioRxiv.
[35] Pedro Rosa-Neto,et al. Synergistic interaction between amyloid and tau predicts the progression to dementia , 2017, Alzheimer's & Dementia.
[36] Ingvild Saltvedt,et al. Association between blood pressure and Alzheimer disease measured up to 27 years prior to diagnosis: the HUNT Study , 2017, Alzheimer's Research & Therapy.
[37] P. Stenson,et al. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies , 2017, Human Genetics.
[38] Gautier Koscielny,et al. Open Targets: a platform for therapeutic target identification and validation , 2016, Nucleic Acids Res..
[39] George Papadatos,et al. The ChEMBL database in 2017 , 2016, Nucleic Acids Res..
[40] Doron Lancet,et al. MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search , 2016, Nucleic Acids Res..
[41] Núria Queralt-Rosinach,et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants , 2016, Nucleic Acids Res..
[42] Jos Prickaerts,et al. From Age-Related Cognitive Decline to Alzheimer's Disease: A Translational Overview of the Potential Role for Phosphodiesterases. , 2017, Advances in neurobiology.
[43] Martin Ringwald,et al. Mouse Genome Informatics (MGI): Resources for Mining Mouse Genetic, Genomic, and Biological Data in Support of Primary and Translational Research. , 2017, Methods in molecular biology.
[44] A. Barabasi,et al. Tissue Specificity of Human Disease Module , 2016, Scientific Reports.
[45] Albert-László Barabási,et al. Endophenotype Network Models: Common Core of Complex Diseases , 2016, Scientific Reports.
[46] Alzheimer’s Association,et al. 2016 Alzheimer's disease facts and figures , 2016, Alzheimer's & Dementia.
[47] Karl Broich,et al. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. , 2016, JAMA neurology.
[48] J. Hardy,et al. The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.
[49] A. Barabasi,et al. Network-based in silico drug efficacy screening , 2016, Nature Communications.
[50] Michael K. Gilson,et al. BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology , 2015, Nucleic Acids Res..
[51] J. Claassen. New cardiovascular targets to prevent late onset Alzheimer disease. , 2015, European journal of pharmacology.
[52] Mulin Jun Li,et al. Nature Genetics Advance Online Publication a N a Ly S I S the Support of Human Genetic Evidence for Approved Drug Indications , 2022 .
[53] A. Barabasi,et al. Uncovering disease-disease relationships through the incomplete interactome , 2015, Science.
[54] Matthew E. Ritchie,et al. limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.
[55] Bridget E. Begg,et al. A Proteome-Scale Map of the Human Interactome Network , 2014, Cell.
[56] J. Cummings,et al. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures , 2014, Alzheimer's Research & Therapy.
[57] Ying Xu,et al. Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice , 2013, Behavioural Brain Research.
[58] Ellen T. Gelfand,et al. The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.
[59] J. Lanciego,et al. Tadalafil crosses the blood–brain barrier and reverses cognitive dysfunction in a mouse model of AD , 2013, Neuropharmacology.
[60] Jie Shen,et al. admetSAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET Properties , 2012, J. Chem. Inf. Model..
[61] L. Mucke,et al. Alzheimer Mechanisms and Therapeutic Strategies , 2012, Cell.
[62] R. Franco,et al. Sildenafil restores cognitive function without affecting β‐amyloid burden in a mouse model of Alzheimer's disease , 2011, British journal of pharmacology.
[63] P. Hof,et al. Carvedilol as a potential novel agent for the treatment of Alzheimer's disease , 2011, Neurobiology of Aging.
[64] K. Pritchard,et al. Inhibition of CDKS by roscovitine suppressed LPS-induced *NO production through inhibiting NFkappaB activation and BH4 biosynthesis in macrophages. , 2009, American journal of physiology. Cell physiology.
[65] R. Jope,et al. Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. , 2009, Cellular signalling.
[66] A. Barabasi,et al. The human disease network , 2007, Proceedings of the National Academy of Sciences.
[67] L. Ferrucci,et al. Comorbidity : The Ultimate Geriatric Syndrome Review Article Methodology , Design , and Analytic Techniques to Address Measurement of Comorbid Disease , 2007 .
[68] H. Ghofrani,et al. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond , 2006, Nature Reviews Drug Discovery.
[69] S. L. Wong,et al. Towards a proteome-scale map of the human protein–protein interaction network , 2005, Nature.
[70] Alex E. Lash,et al. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..
[71] Y. Benjamini,et al. THE CONTROL OF THE FALSE DISCOVERY RATE IN MULTIPLE TESTING UNDER DEPENDENCY , 2001 .
[72] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.